Compare Quest Diagnostics Inc (DGX) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs ProShares Ultra Gold ETF — how do they compare? Quest Diagnostics Inc trades at $204.68 (market cap $22.80B), while ProShares Ultra Gold ETF trades at $44.56. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while ProShares Ultra Gold ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals.
| DGX | UGL | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $216.02 | $85.62 |
52-Week Low | $166.42 | $33.59 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
UGL trades at $43.38, down 5.2% over 24 hours amid a bearish technical outlook with 19 sell signals versus 2 buys. The stock faces resistance at $44 and $45, with support at $43 and $42. Financial ratios are unavailable, limiting fundamental clarity. Recent news highlights gold market volatility, with prices influenced by Fed policy, inflation data, and geopolitical tensions, though UGL's direct exposure is not detailed.
The outlook remains cautious due to weak technical momentum and lack of financial data. Risks include gold price sensitivity to interest rates and macroeconomic shifts. Investors should await earnings reports for fundamental validation, as current analysis relies heavily on technical indicators and broader sector sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
